Ivan King

2.0k total citations
39 papers, 1.6k citations indexed

About

Ivan King is a scholar working on Molecular Biology, Biotechnology and Oncology. According to data from OpenAlex, Ivan King has authored 39 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 14 papers in Biotechnology and 11 papers in Oncology. Recurrent topics in Ivan King's work include Cancer Research and Treatments (13 papers), Nanoplatforms for cancer theranostics (8 papers) and Virus-based gene therapy research (6 papers). Ivan King is often cited by papers focused on Cancer Research and Treatments (13 papers), Nanoplatforms for cancer theranostics (8 papers) and Virus-based gene therapy research (6 papers). Ivan King collaborates with scholars based in United States, Australia and United Kingdom. Ivan King's co-authors include David Bermudes, Li-Mou Zheng, Stanley L. Lin, Martina Ittensohn, Mario Sznol, Trung Bao Le, Xiang Luo, Alan C. Sartorelli, K. Brooks Low and John M. Pawelek and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Nature Biotechnology.

In The Last Decade

Ivan King

38 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ivan King United States 18 1.1k 730 601 386 235 39 1.6k
Hans Peter Sørensen Denmark 16 297 0.3× 152 0.2× 524 0.9× 1.8k 4.6× 231 1.0× 26 2.3k
M. Gabriela Kramer Spain 22 155 0.1× 115 0.2× 495 0.8× 600 1.6× 170 0.7× 47 1.3k
Jari Helin Finland 26 262 0.2× 82 0.1× 265 0.4× 1.6k 4.0× 203 0.9× 62 2.4k
Hui Cai China 30 208 0.2× 242 0.3× 118 0.2× 1.7k 4.5× 256 1.1× 84 2.7k
Øystein Rekdal Norway 34 180 0.2× 178 0.2× 217 0.4× 1.9k 5.0× 67 0.3× 68 3.0k
Hiroshige Tsuzuki Japan 27 599 0.6× 58 0.1× 204 0.3× 1.6k 4.0× 71 0.3× 58 2.4k
Xiaoying Chen China 11 158 0.1× 134 0.2× 120 0.2× 1.2k 3.1× 123 0.5× 25 1.7k
Mark Vasser United States 12 156 0.1× 114 0.2× 554 0.9× 1.6k 4.1× 269 1.1× 17 1.9k
P. Turner United States 33 85 0.1× 272 0.4× 588 1.0× 1.2k 3.2× 168 0.7× 73 3.2k
Mahdi Behdani Iran 24 153 0.1× 137 0.2× 239 0.4× 1.1k 2.9× 80 0.3× 136 1.8k

Countries citing papers authored by Ivan King

Since Specialization
Citations

This map shows the geographic impact of Ivan King's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ivan King with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ivan King more than expected).

Fields of papers citing papers by Ivan King

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ivan King. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ivan King. The network helps show where Ivan King may publish in the future.

Co-authorship network of co-authors of Ivan King

This figure shows the co-authorship network connecting the top 25 collaborators of Ivan King. A scholar is included among the top collaborators of Ivan King based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ivan King. Ivan King is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tsimberidou, Apostolia M., Farshid Dayyani, David Sommerhalder, et al.. (2025). Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumors. The Oncologist. 30(7).
2.
Azad, Arun, Craig Underhill, Howard Gurney, et al.. (2024). Biomarker assessment and pharmacology of HP518, an AR PROTAC degrader from the phase 1 dose-escalation study in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 42(16_suppl). 5058–5058. 1 indexed citations
3.
Nassar, Ala F., Adam V. Wisnewski, & Ivan King. (2015). Metabolic disposition of the anti-cancer agent [14C]laromustine in male rats. Xenobiotica. 45(8). 711–721. 1 indexed citations
4.
King, Ivan, et al.. (2009). Tumor-Targeted Salmonella typhimurium Overexpressing Cytosine Deaminase: A Novel, Tumor-Selective Therapy. Methods in molecular biology. 542. 649–659. 21 indexed citations
5.
Zheng, Li-Mou, et al.. (2007). Anti-tumor efficacy of Cloretazine (VNP40101M) alone and in combination with fludarabine in murine tumor and human xenograft tumor models. Cancer Chemotherapy and Pharmacology. 60(1). 45–51. 4 indexed citations
6.
Badruddoja, Michael, Stephen T. Keir, Ivan King, et al.. (2007). Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice. Neuro-Oncology. 9(3). 240–244. 5 indexed citations
7.
Yee, Karen, Jörge E. Cortes, Alessandra Ferrajoli, et al.. (2006). Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. Leukemia Research. 30(7). 813–822. 41 indexed citations
8.
Wang, Qin, Lanzhen Liu, Michael F. Belcourt, et al.. (2005). Combination of KS119W with other antitumor agents for the treatment of murine and human tumor xenografts in mice. Cancer Research. 65. 325–325. 1 indexed citations
9.
Bermudes, David, K. Brooks Low, John M. Pawelek, et al.. (2001). Tumour-SelectiveSalmonella-BasedCancer Therapy. Biotechnology and Genetic Engineering Reviews. 18(1). 219–233. 16 indexed citations
10.
11.
Sznol, Mario, Stanley L. Lin, David Bermudes, Li-Mou Zheng, & Ivan King. (2000). Use of preferentially replicating bacteria for the treatment of cancer. Journal of Clinical Investigation. 105(8). 1027–1030. 139 indexed citations
12.
Low, K. Brooks, Martina Ittensohn, Trung Bao Le, et al.. (1999). Lipid A mutant Salmonella with suppressed virulence and TNFα induction retain tumor-targeting in vivo. Nature Biotechnology. 17(1). 37–41. 407 indexed citations
13.
Chen, Shu‐Hui, Qin Wang, John Mao, et al.. (1998). Synthesis and biological evaluation of a series of 2′-fluorinated-2′,3′-dideoxy-2′,3′-didehydro-(l)-nucleosides. Bioorganic & Medicinal Chemistry Letters. 8(13). 1589–1594. 10 indexed citations
14.
Li, Xiuyan, et al.. (1998). Bis-S-acyl-2-thioethyl (sate)-bearing monophosphate prodrug of β-L-FD4C as potent anti-HBV agent. Bioorganic & Medicinal Chemistry Letters. 8(1). 57–62. 6 indexed citations
15.
Chen, Shu‐Hui, Stanley L. Lin, Ivan King, et al.. (1998). Synthesis and comparative evaluation of two antiviral agents: β-l-Fd4C and β-d-Fd4C. Bioorganic & Medicinal Chemistry Letters. 8(22). 3245–3250. 16 indexed citations
16.
Hayashi, Moriaki, Mikio Tomida, Motoo Hozumi, Ivan King, & Alan C. Sartorelli. (1996). Detection of in vivo differentiation of murine WEHI-3B D+ leukemia cells transfected with the lac-Z marker gene using two-color flow cytometry. Leukemia Research. 20(4). 333–341. 4 indexed citations
17.
King, Ivan, et al.. (1993). High throughput assay for inhibitors of the epidermal growth factor receptor-associated tyrosine kinase. Life Sciences. 53(19). 1465–1472. 12 indexed citations
18.
King, Ivan, et al.. (1990). Nonradioactive ligand binding assay for epidermal growth factor receptor. Analytical Biochemistry. 188(1). 97–100. 14 indexed citations
19.
Violette, Shelia M., et al.. (1989). Antagonistic Effects of Retinoic Acid and Hydrocortisone on Terminal Differentiation of Human Squamous Carcinoma Cells. Journal of Investigative Dermatology. 93(1). 165–168. 8 indexed citations
20.
Violette, Shelia M., Ivan King, & Alan C. Sartorelli. (1989). Induction of the terminal differentiation of a human squamous cell carcinoma by steroids with glucocorticoid activity. Journal of Steroid Biochemistry. 33(5). 1001–1005. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hans Peter Sørensen Breakdown of academic impact, for papers by M. Gabriela Kramer Breakdown of academic impact, for papers by Jari Helin Breakdown of academic impact, for papers by Hui Cai Breakdown of academic impact, for papers by Øystein Rekdal Breakdown of academic impact, for papers by Hiroshige Tsuzuki Breakdown of academic impact, for papers by Xiaoying Chen Breakdown of academic impact, for papers by Mark Vasser Breakdown of academic impact, for papers by P. Turner Breakdown of academic impact, for papers by Mahdi Behdani
Rankless by CCL
2026